Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension

A Pilot Phase IIa Randomised, Double-blind, Placebo-controlled, Crossover Study to Examine the Safety, Tolerability and Pharmacodynamic Effects on Blood Pressure of Repeat Oral Doses of SLx-2101 5 mg or 10 mg Once Daily for up to 14 Days in Patients With Hypertension

The purpose is to determine the effect of SLx-2101 dosed at 5mg or 10mg for 14 days on systolic, diastolic pressures and heart rate in patients with hypertension.

1. Placebo-corrected supine peripheral systolic, diastolic blood pressures and heart rate
2. 24 hour ambulatory blood pressure and heart rate
3. Safety and tolerability

Inclusion Criteria:

• Male or female subjects between 18 and 70 years old, inclusive
• Moderate to severe hypertension
• Body weight within a body mass index of 18-32kg/m2

Exclusion Criteria:

• The subject is receiving more than three antihypertensive agents
• A history of drug abuse
• Exposure to a new chemical entity within 3 months prior to the first day of dosing